Using cancer genetics to guide the selection of anticancer drug targets

Current Opinion in Pharmacology

Volumn 2, Issue 4, 2002, Pages 366-373

  Reddy, Archana ^a   Kaelin, William G ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; IMATINIB; MESSENGER RNA; RAPAMYCIN; TRANSCRIPTION FACTOR E2F;

ARTICLE; BIOCHEMISTRY; CANCER CELL; CANCER GENETICS; CANCER SURVIVAL; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TARGETING; GENE MUTATION; HUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; SOMATIC CELL GENETICS; ANIMAL; DRUG DELIVERY SYSTEM; GENETICS; METHODOLOGY; NEOPLASM; PHARMACEUTICS; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMAN; NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TECHNOLOGY, PHARMACEUTICAL; ANIMALS; HUMANS;

EID: 0036667382     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00178-9     Document Type: Review

References (56)

1. TISCS. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
2. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
3. + leukemia: Recent insights from mouse models
4. How many mutations are required for tumorigenesis
5. Creation of human tumour cells with defined genetic elements
6. Lessons from hereditary colorectal cancer
7. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain
8. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells
9. Tumor suppression by the human von Hippel-Lindau gene product
10. Suppression of human colorectal carcinoma cell growth by wild-type p53
11. Essential role for oncogenic Ras in tumour maintenance
12. Reversible tumorigenesis by MYC in hematopoietic lineages
13. Trastuzumab: A review of its use in the treatment of metastatic breast cancer overexpressing HER2
14. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor
15. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study
16. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
17. Cancer treatment in the STI571 era: What will change?
18. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
19. Targeting c-kit mutations in solid tumors: Scientific rationale and novel therapeutic options
20. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
21. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
22. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors
23. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications
24. EORTC. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: A phase I study
25. Effect of the tyrosine kinase inhibitor ST1571 in a patient with a metastatic gastrointestinal stromal tumor
26. Choosing anticancer drug targets in the postgenomic era
27. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
28. Systematic variation in gene expression patterns in human cancer cell lines
29. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
30. Molecular classification of human carcinomas by use of gene expression signatures
31. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
32. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
33. Integrating genetic approaches into the discovery of anticancer drugs
34. Proteasome inhibition in cancer: Development of PS-341
35. Geldanamycin: The prototype of a class of antitumor drugs targeting the heat shock protein 90 family of molecular chaperones
36. Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae
37. Principles for the buffering of genetic variation
38. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
39. Identification of E2F-1/Cyclin A antagonists
40. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
41. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice
42. Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo
43. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt
44. ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation
45. Use of isogenic human cancer cells for high-throughput screening and drug discovery
46. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications
47. Establishment of a chemical synthetic lethality screen in cultured human cells
48. Caenorhabditis elegans p53: Role in apoptosis, meiosis, and stress resistance
49. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53
50. Drosophila p53 binds a damage response element at the reaper locus
51. Genetic synthetic lethality screen at the single gene level in cultured human cells
52. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
53. A system for stable expression of short interfering RNAs in mammalian cells
54. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
55. Cancer chemotherapy based on E2F and the retinoblastoma pathway
56. Anoikis mechanisms